Drug Discovery World

APRIL 4, 2023

The designation is the first step to gaining a priority review voucher (PRV), which can accelerate market access for therapeutics. The Food and Drug Administration (FDA) in the US has made several key drug decisions over the last few weeks. Here’s a summary. The drug was granted orphan drug designation by the FDA in May 2021.

FDA Approval 52

FDA Approval In-Vivo Gene Editing Drugs 52

Drug Discovery World

MAY 10, 2023

Due to the high costs associated with new drug development, pharmaceutical companies are under pressure to get effective drugs to market as fast as possible while ensuring they are safe for the intended patient population and dosing timeline, which can be lifelong for some drugs. billion and take over 10 years.

Bioassay 52

Bioassay Genotoxicity Drugs In-Vivo 52

The Pharma Data

OCTOBER 14, 2020

VBL has recently demonstrated ex-vivo activity of anti-MOSPD2 antibodies in patients with relapsing-remitting and progressive multiple sclerosis (MS), as well as in animal models of rheumatoid arthritis (RA), nonalcoholic steatohepatitis (NASH) and inflammatory bowel disease (IBD). 1. -- -->. -- [if lte IE 8]--> .

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52